13F Holdings
中文EN

AMLX Amylyx Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1658551 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.3%
TTM net income YoY42.5%
TTM EPS YoY53.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin23,660.3%
Net margin22,448.4%
FCF margin23,236.1%
EBITDA margin23,573.5%

Returns

ROE-56.5%
ROA-48.7%
ROIC (approx.)-107.5%
Asset turnover-0.00x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio13.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue-10.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$87.37M$380.79M$22.23M$285,000
Cost of revenue$0$5.95M$25.44M$2.99M—
Gross profit$0$81.42M$355.35M$19.24M—
R&D expense$90.40M$104.08M$128.19M$93.45M$44.04M
SG&A expense$62.89M$114.33M$188.36M$127.13M$38.93M
Operating income-$153.29M-$314.73M$38.80M-$201.34M-$82.69M
Pretax income-$144.69M-$302.14M$54.30M-$197.60M-$87.93M
Income tax$46,000-$393,000$5.03M$774,000—
Net income-$144.74M-$301.74M$49.27M-$198.38M-$87.93M
EBITDA-$152.77M-$313.83M$39.89M-$200.85M-$82.64M
EPS (basic)-1.53-4.430.73-3.39-13.35
EPS (diluted)-1.53-4.430.70-3.39-13.35
Weighted avg. shares (diluted)94.57M68.14M69.99M58.50M6.59M
Balance sheet
Cash & equivalents$226.65M$77.39M$170.20M$62.53M$50.19M
Short-term investments$90.33M$99.11M$201.16M$284.42M$45.93M
Receivables$88,000$447,000$40.05M$15.31M—
Inventory——$38.32M$9.77M—
Current assets$323.67M$189.43M$464.67M$382.13M$104.95M
PP&E, net$310,000$961,000$2.69M$2.61M$474,000
Total assets$332.64M$193.63M$517.45M$391.45M$105.61M
Current liabilities$22.69M$28.41M$82.04M$46.61M$17.40M
Total liabilities$27.39M$28.87M$84.02M$50.85M$17.43M
Shareholders' equity$305.26M$164.76M$433.43M$340.61M-$151.17M
Shares outstanding109.88M68.63M67.71M66.51M7.02M
Cash flow statement
Operating cash flow-$123.34M-$167.65M$11.92M-$179.87M-$74.80M
Capital expenditure$138,000$157,000$1.24M$2.53M$353,000
Free cash flow-$123.48M-$167.80M$10.68M-$182.40M-$75.15M
Investing cash flow$14.04M$75.65M$92.05M-$238.99M-$46.41M
Financing cash flow$257.03M$348,000$3.54M$431.79M$158.51M
Depreciation & amortization$525,000$904,000$1.09M$487,000$52,000
Stock-based compensation$27.64M$33.04M$37.16M$21.71M$3.14M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.